Teva gains approval of biosimilar of Amgen's Prolia
Source: SeekingAlpha
2026-03-30 11:01:40 ET
More on Teva Pharmaceutical
- Teva: Shedding The Generics Skin To Reveal A Fairly Priced, Branded Powerhouse
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Leerink Global Healthcare Conference 2026 Transcript
- Generic drug suppliers could face pressure from Strait of Hormuz closure
- FDA issues draft guidance to relax testing rules to encourage biosimilar drugs
Read the full article on Seeking Alpha
For further details see:
Teva gains approval of biosimilar of Amgen's Prolia
Novartis AG
NASDAQ: NVS
NVS Trading
-0.26% G/L:
$150.47 Last:
852,043 Volume:
$151.84 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
